摘要
青蒿素类药物抗疟机制尚未明确,目前较主流的多种青蒿素抗疟机制学说提示,青蒿素类药物可能存在多方面多途径的抗疟机制;另一方面,疟原虫在体内的发病机制相对明确,其中关于疟疾发病的"红细胞膜疟原虫诱生阴离子通道(PSAC)"研究揭示,红细胞感染疟原虫后,红细胞膜可以选择性增高对疟原虫生长增殖所需的红细胞外糖醇、嘌呤和氨基酸等阴离子营养物质的透膜运输,采用阴离子通道抑制剂可以抑制红内期疟原虫对胞外营养物质的摄取,阻断疟原虫的发育增殖。该文研究双氢青蒿素(DHA)体外对人源性HB3疟原虫感染人红细胞膜通透性的影响,以提示青蒿素类药物是否可以通过抑制红细胞膜通透性,发挥阻止和杀灭疟原虫红内期生长增殖作用。实验采用5%山梨醇可以透过红细胞膜特异性杀灭红内期疟原虫的原理,观察体外HB3培养体系中施加DHA与否,山梨醇对红内期疟原虫的杀灭效果差异,考察DHA是否可以影响疟原虫感染红细胞膜的通透性;结果显示,10 nmol·L-1的DHA(疟原虫体外培养体系终浓度)预刺激30 min后,可以显著减弱山梨醇对红内期HB3疟原虫的杀灭作用,DHA有可能是通过抑制疟原虫感染红细胞膜的通透性,阻碍了山梨醇透过红细胞膜,从而减弱了山梨醇对红内期疟原虫的杀灭作用。
In view of the fact that the antimalarial effects of artemisinins are significant but the mechanism has not yet been clarified and there are many different opinions,it is possible that artemisinins can produce high anti-malarial efficacy through various mechanisms and multiple pathways. In addition,the researches on the pathogenesis of malaria " erythrocyte membrane plasmodial surface anion channel( PSAC) " in the past few years have provided more positive findings,which may confirm and discover the new antimalarial mechanism of artemisinins. This paper was as to study the effect of dihydroartemisinin( DHA) in vitro on erythrocyte membrane permeability of HB3 plasmodium infection,with using the mechanism of 5% sorbitol can be used to kill the Plasmodium falciparum in red blood cell membrane selectively,the effectual difference of sorbitol on the killing of P. falciparum with adding DHA or not was detected,so as to investigate whether DHA can affect the permeability of the erythrocyte membrane. Result showed that,Pre-stimulation with 10 nmol·L-1 DHA( the final concentration of plasmodium in vitro culture system) for 30 min could significantly decrease the killing effect of sorbitol on the HB3 plasmodium in the P. falciparum erythrocytic cycle,and DHA may inhibit the permeability of the erythrocyte membrane for preventing sorbitol through the red blood cell membrane,thereby reducing the killing effect of sorbitol on the P. falciparum.
作者
谷丽维
李玉洁
蔡维艳
陈利娜
陈颖
杨庆
王娅杰
李琦
朱晓新
翁小刚
GU Li-wei;LI Yu-jie;CAI Wei-yan;CHEN Li-na;CHEN Ying;YANG Qing;WANG Ya-jie;LI Qi;ZHU Xiao-xin;WENG Xiao-gang(Institute of Chinese Materia Medica & Research Center of Artemisinin,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2018年第17期3589-3594,共6页
China Journal of Chinese Materia Medica
基金
国家自然科学基金特别项目(81641002)
国家自然科学基金青年基金项目(81603346)
北京市自然科学基金面上项目(7152105)
中国中医科学院自主选题研究项目(ZZ070835)